Methods developed and validated to establish the “World Bank of NK Cells” from healthy donors and cancer patientsSingle ...

The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at ...

Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...

In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...

The European Commission (EC) on Friday approved Incyte’s Zynyz (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult ...

Treatment Phase for Lead Clinical Candidate PH-762 Dose Escalation Trial is Complete with Favorable Safety, Tolerability and Pathology Data 2025 Financings and Warrant Exercises Strengthen Balance ...

The U.S. Food and Drug Administration (FDA) declined approval of retifanlimab-dlwr for patients with metastatic non-small cell lung cancer (NSCLC) in the United States because of manufacturing ...

Incyte has received European Commission approval for Zynyz (retifanlimab) in combination with carboplatin and paclitaxel as a ...

Fred Hutch Cancer Center medical oncologist Dr. Lisa Tachiki has been named a 2025 Cancer Research Fellow by the Kuni Foundation, an honor that includes an unrestricted, two-year $300,000 award.

Skin cancer is the most common cancer in the U.S. Learn the main types, warning signs, and the prevention tip dermatologists say not to skip.

Barclays 28th Annual Global Healthcare Conference March 11, 2026 9:30 AM EDTCompany ParticipantsSara Pellegrino ...